Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

It’s the latest move in the race by drug companies to corner more of the highly-lucrative obesity drug market.

This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...